Navigation Links
Sphingomab in Medical Technology

Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug Candidate, Sphingomab

Sphingomab Shows Near-Complete Mitigation of Choroidal Neovascularization (CNV) in an AMD Model SAN DIEGO, May 22, 2007 /PRNewswire-FirstCall/ -- Lpath, Inc. , the category leader in therapeutic agents against bioactive lipids, reported compelling proof-of-concept data in a standard animal model o...

Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process

...ing with them again on our Lpathomab project." This achievement with Lpathomab comes on the heels of Lpath's success with its Sphingomab(TM) program. sphingomab is an antibody against another bioactive lipid, S1P. Lpath humanized the antibody in 2006 and plans to file an IND in November of this year for the us...

Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates

...udy included evaluation of the effect of humanized sphingomab treatment on blood pressure, heart rate, and respi...r, cytokine release, and ADCC tests with humanized sphingomab were all negative at doses or concentrations well ...y featured intravenous administration of humanized sphingomab at doses as great as 100 mg/kg every three days fo...
Sphingomab in other areas

About - Business & Finance - MEDIAVIEWER

Sphingomab is potently anti-angiogenic, yet it has other ... As such, Lpath believes Sphingomab may represent the next ... Sphingomab is a trademark ...

PipelineReview.com - Biotech News & Online Store - Lpath Humanizes Its ...

... Biopharmaceutical Industry, Lpath Humanizes Its Anti-S1P Antibody Sphingomab(TM) ... murine (mouse-based) form of Sphingomab was the first antibody created ...

PipelineReview.com - Biotech News & Online Store - Lpath Demonstrates ...

... Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM... Sphingomab, generated by Lpath's proprietary ImmuneY2(TM) platform ...

Novel Drug Stops Cancer Growth

A first-of-its-kind drug effectively targets a molecule that fuels cancer cells and shows promise for stopping the ... Sphingomab is a monoclonal antibody. ...

Lpath granted patent protection for anti-cancer anti-S1P antibody.

Lpath, Inc. (San Diego, CA) , the category leader in therapeuticagents against bioactive lipids, announced the issuance ... Sphingomab is potently anti ...
Other Tags
(Date:4/1/2015)... (PRWEB) April 01, 2015 Dr Roz ... that she is now offering her patients an opportunity ... Patients can participate in “Beauty Days”, which is an ... Dr Roz Kamani’s Kitsilano Skin Care Clinic. It is ... tell patients about the latest products and services that ...
(Date:4/1/2015)... Tempaper has joined forces with the Muscular Dystrophy Association ... raise critical funds to help save and improve the ... States. , Throughout the month of April, anyone who ... receive free domestic ground shipping on all orders while ... children and adults affected by muscular dystrophy and related ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 IQ Formulations ... health and nutritional supplement companies in the U.S., today is ... testing and quality control standards for its herbal supplements.* GNC ... supply chain to ensure the accuracy of labeling on its ... veteran and IQ Formulations CEO Jay Cohen said: ...
(Date:4/1/2015)... When annoying or concerning skin conditions such as ... an appointment with a dermatologist is the last thing ... been possible within dermatology. However, in the Sheboygan and ... for this level of service and are answering consumer’s ... answers to dermatological issues are to our patients, and ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 The ... Calcium Industry is a professional and in-depth study ... Atorvastatin Calcium Market with a focus on ... atorvastatin calcium market research are Pfizer, Lek Pharmaceuticals ... Sinochem Pharmaceuticals India Private Limited, Cadila Healthcare Limited, ...
Breaking Medicine News(10 mins):Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 3Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2Health News:Atorvastatin Calcium Industry International & China Market Analysis 2015-2020 2Health News:Atorvastatin Calcium Industry International & China Market Analysis 2015-2020 3
(Date:4/1/2015)... 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces the second ... is underway to early access pre-order customers. ... at retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, ... was accepted at all outlets and very easy to ...
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
Other Contents